Executive Management Team

Born: 1961

Employed since: 2013

Other assignments: Board member of Egetis Therapeutics AB.

Education: Pharmacist; Ph.D. in biopharmacy and pharmacokinetics at Uppsala University, Sweden.

Experience and prior assignments: More than 35 years of experience in drug development. Executive positions at Astra/AstraZeneca, including Vice President responsible for the product portfolio in neurodegenerative diseases. Board member of SP Process Development AB.

Member of BioArctic’s senior management since: 2013

Total holdings* and warrants in BioArctic: 72,000 Class B shares. Warrants granting acquisition rights to 20,000 Class B shares (2019/2028 program). 10,000 performance-based share units (2023/2026 program). 10,000 performance-based share units (2024/2027 program). 10,000 performance-based share units (2025/2028 program).

Born: 1971

Employed at the company since: 2023

Other assignments: Board member of Cantargia Ab and Affibody Medical AB.

Education: Master’s degree in Engineering Physics from KTH Royal Institute of Technology in Stockholm, and bachelor’s degree in Economics from Stockholm University.

Experience and prior assignments: Lengthy experience as CFO for life science companies listed on the Stockholm Stock Exchange, and was previously CFO for Oncopeptides, Wilson Therapeutics and RaySearch Laboratories. Also Head of Investor Relations and held various business development positions at Swedish Orphan Biovitrum.. 

Member of BioArctic’s senior management since: 2023

Total holdings* and warrants in BioArctic: 2,500 Class B-shares. Employee stock options that grant acquisition rights to 20,000 Class B-shares (2019/2028 program). 3,000 performance-based share units (2023/2026 program). 3,000 performance-based share units (2024/2027 program). 5,000 performance-based share units (2025/2028 program). 

Born: 1981

Employed since: 2024

Other assignments: –

Education: Master of Laws (Jur.kand.) from Uppsala University, Sweden.

Experience and prior assignments: More than 18 years of experience in the Life Science industry with roles such as Legal Counsel, Public Affairs Manager, Business Unit Manager, and Senior Legal Counsel. Previously worked at the industry organization Swedish Medtech and global companies Roche Diagnostics and Bayer.

Member of BioArctic’s senior management since: 2025

Total holdings* and warrants in BioArctic: 9 Class B shares. Warrants granting acquisition rights to 3000 performance-based share units (2024/2027 program). 5,000 performance-based share units (2025/2028 program).

Born: 1976

Employed since: 2020

Other assignments: –

Education: Engineering degree in molecular biotechnics and bachelor’s degree in business administration from Uppsala University.

Experience and prior assignments: Over 20 years of experience globally in communications. Has previously held senior positions in companies such as Sobi, Ovako and Elekta.

Member of BioArctic’s senior management since: 2020

Total holdings* and warrants in BioArctic: 7,214 Class B-shares. 3,000 performance-based share units (2023/2026 program). 3,000 performance-based share units (2024/2027 program). 5,000 performamce-based share units (2025/2028 program).

Born: 1972

Employed since: 2012

Other assignments: Member of the Swedish Resarch Council, expert for medicine and health. Board member of Syntetic MR.

Education: Ph.D. in Physiology, Stockholm University; Licentiate degree in physiology, Stockholm University; Master’s degree in biology, Stockholm University, Sweden.

Experience and prior assignments: Over 20 years of experience in drug development in executive positions in R&D, and development in the global pharma and biotech industry.

Member of BioArctic’s senior management since: 2012

Total holdings* and warrants in BioArctic: 20,885 Class B-shares. 3,000 performance-based share units (2023/2026 program). 3,000 performance-based share units (2024/2027 program). 5,000 performance-based share units (2025/2028 program).

Born: 1968

Employed since: 2021 (contracted since 2020)

Other assignments: –

Education: B.Sc. in Business Administration from Uppsala University, Sweden.

Experience and prior assignments: More than 25 years of experience in executive commercial roles in the global pharma industry. Former CEO of Sanofi AB and board member of Läkemedelsindustriföreningen (LIF) and Index Pharmaceuticals AB.

Member of BioArctic’s senior management since: 2021

Total holdings* and warrants in BioArctic: 11,000 Class B-shares. Employee stock options that grant acquisition rights to 10,000 Class B-shares (2019/2028 program). 3,000 performance-based share units (2023/2026 program). 3,000 performance-based share units (2024/2027 program). 5,000 performance-based share units (2025/2028 program).

Born: 1978

Employed since: 2024

Other assignments: Board member/ CEO Skala Tio AB, Deputy Board member Azio AB, Baseline Retail AB, Revictus AB

Education: Lic. Psychologist. B.A. in Social Science- Psychology, Bond University, Australia. Masters in Psychology (Cand. Psych), Copenhagen University, Denmark. Executive MBA from Stockholm School of Economics, Sweden.

Experience and prior assignments: More than 20 years of experience in Organizational Psychology, Human Resources and M&A in state-owned, public and private companies. Executive HR position in the medical device and healthcare tech industry.

Member of BioArctic’s senior management since: 2025

Total holdings and warrants in BioArctic: 3,000 performance-base share units (2024/2027 program). 5,000 performance-based share units (2025/2028 program).

Born: 1967

Employed since: 2012

Other assignments –

Education: Master of Chemical Engineering, KTH Royal Institute of Technology; Ph.D. in organic chemistry, KTH; Stockholm, Sweden.

Experience and prior assignments: Over 25 years of experience in drug development and more than 20 years of experience as R&D director in process development and GMP manufacturing. Former section manager in Process R&D at AstraZeneca.

Member of BioArctic’s senior management since: 2012

Total holdings* and warrants in BioArctic: 11,970 Class B-shares. 3,000 performance-based share units (2023/2026 program). 3,000 performance-based share units (2024/2027 program). 5,000 performance-based share units (2025/2028 program).

Born: 1961

Employed since: 2023

Other assignments –

Education: Medical degree from Karolinska Institutet, PhD from Karolinska Institutet, neurologist certified by the Swedish Society of Medicine, diploma in pharmaceutical medicine from Karolinska Institutet/The Swedish Medical Products Agency.

Experience and prior assignments: Over 20 years of experience in the pharma industry, in leading positions in clinical research at AstraZeneca and H. Lundbeck. Chief Specialist Neurology H Lundbeck A/S (2017–2023).

Total holdings* and warrants in BioArctic: 400 Class B-shares. Employee stock options that grant acquisition rights to 20,000 Class B-shares (2019/2028 program). 3,000 performance-based share units (2023/2026 program). 3,000 performance-based share units (2024/2027 program). 5,000 performance-based share units (2025/2028 program). 

Born: 1975

Employed since: 2018

Other assignments: –

Education: Ph.D. in Neurobiology, Lund University, Sweden; M.Sc. in Chemistry, Högskolan i Kalmar, Sweden

Experience and prior assignments: Experience in drug discovery and development from the last 20 years including leadership positions in global pharma and biotech industry.

Member of BioArctic’s senior management since: 2025

Total holdings* and warrants in BioArctic: 1,796 Class B shares. Warrants granting acquisition rights to 3,000 Class B shares (2019/2028 program). 3,000 performance-based share units (2023/2026 program). 3,000 performance-based share units (2024/2027 program). 5,000 performance-based share units (2025/2028 program).